Kyverna Therapeutics, Inc.

NASDAQ:KYTX

Biotechnology

Healthcare
$4.48 -1.44%

-$0.12 today

Market cap
$283.23M
Beta
1.96
P/E (TTM)
-3.1
EPS (TTM)
-$2.59
52W Low $2.52High $13.67

Volume 1.05M

Average 0.94M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$153.71M

FY 2025 · Annual

Investing Cash Flow

$40.02M

FY 2025 · Annual

Financing Cash Flow

$141.17M

FY 2025 · Annual

-58.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.35M)(28.89M)(60.37M)(127.48M)(161.31M)
Depreciation & Amortization586K1.05M1.71M2.13M1.8M
Deferred Income Tax00000
Stock-Based Compensation7.25M929K2.22M8.36M10.08M
Change in Working Capital(4.49M)(10.33M)3.42M7.86M(1.08M)
Accounts Receivables00000
Inventory00000
Accounts Payables11K677K4.08M736K543K
Other Working Capital(4.5M)(11M)(659K)7.12M(1.62M)
Other Non-Cash Items850K1.13M605K(5.12M)(3.21M)
Operating Cash Flow(22.16M)(36.11M)(52.41M)(114.25M)(153.71M)
Capital Expenditures(1.29M)(768K)(621K)(2.21M)(5K)
Acquisitions (Net)000070K
Purchases of Investments0(56.5M)(54.85M)(490M)(364.62M)
Sales of Investments043.17M46.68M323.64M398.81M
Other Investing Activities0007.66M5.76M
Investing Cash Flow(1.29M)(14.1M)(8.79M)(160.9M)40.02M
Debt Repayment(41K)(249K)(781K)(956K)23.89M
Common Stock Issued000341.17M117.42M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities30K175K(1M)(3.1M)(144K)
Financing Cash Flow72.52M11.88M58.12M337.11M141.17M
Effect of Forex Changes00000
Net Change in Cash49.08M(38.33M)(3.08M)61.96M27.47M
Free Cash Flow(23.44M)(36.88M)(53.03M)(116.46M)(153.72M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$161.3M
+ D&A$1.8M
+ Stock-Based Comp$10.1M
+ Deferred Tax$0
- Working Capital-$1.1M
- Other Non-Cash-$3.2M
= Operating Cash Flow-$153.7M
- Capex-$5.0K
= Free Cash Flow-$153.7M

Analysis

FY2025 free cash flow is -$153.7M. FCF conversion is 95.3% of net income. Operating cash flow was -$153.7M, with capex of -$5.0K. The largest bridge item is Stock-Based Comp at $10.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 12, 2026
10-QQuarterly reportNov 12, 2026
SC 13GSC 13G filingOct 19, 2026
8-KCurrent reportSep 24, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

Does KYTX generate free cash flow?

Kyverna Therapeutics, Inc. (KYTX) generated -$153.72M of free cash flow in fiscal 2025.

How much operating cash flow does KYTX produce?

Operating cash flow was -$153.71M, before capital expenditures of $5,000.00.